Personalized immunotherapy is emerging as the latest frontier in cancer treatment.

Judy Perkins, a 52-year-old breast cancer patient, had been in remission for a decade when her cancer returned with a vengeance. She stopped responding to treatment and was grappling with a terminal diagnosis. But then Perkins learned about a National Institutes of Health trial that involved the extraction of immune cells to treat cancer. She enrolled, went for treatment and, within months, her advanced breast cancer was eradicated through the use of immunotherapy tailored to fight her tumors. She dodged a bullet.

A definitive cure for cancer has remained elusive despite years of steady advancements in treatment. Cancer killed 8.8 million people in 2015 worldwide, according to the WHO. But the rise of personalized and precision medicine like Perkins had now promises to transform cancer treatment. Everybody — and every cancer — is different, and the development of genome sequencing has paved the way toward a new cancer treatment tuned to those unique qualities: personalized immunotherapy.

Forged in sweltering Texas gyms, this cocky 28-year-old has big dreams.

As chaos erupts around him, Errol Spence Jr. simply smiles and saunters into the boxing ring. It is his homecoming — the first time he’ll defend his title in the Dallas area — and he has everything to lose. A defeat at the hands of Carlos Ocampo, a largely unknown Mexican boxer regarded highly enough to make him a mandatory opponent, would cost Spence millions and a spot among the top pound-for-pound boxers in the world. And yet, with everything on the line and seemingly everyone in the crowd of more than 12,600 screaming in anticipation, Spence appears calm, as always.

A highly decorated amateur and 2012 Olympian, Spence has thrown his hat into the ring with the world’s best boxers. His success is the sport’s success, helping secure its future in the United States — while putting to bed the tired notion that boxing is dead.

Salim Zerrouki is asking Arabs to shed conspiracy theories of a Western plot against them.

Salim Zerrouki calls 100% Bled, the title of his new graphic novel, “insipid.” Most people, though, would find it fairly provocative — a fair representation of the book’s content, which mocks Arabs in the Maghreb for blaming others for their problems. But Zerrouki, 40, had suggested an even more daring title at first: How to Improve the World by Getting Rid of the Arabs. He and his French publishers compromised, but they still chose a title that captures Zerrouki’s mission: to constantly provoke the society he’s part of — risks be damned.